Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent

被引:30
作者
Reddel, C. J. [1 ]
Allen, J. D. [2 ]
Ehteda, A. [2 ]
Taylor, R. [2 ]
Chen, V. M. Y. [1 ,3 ]
Curnow, J. L. [4 ]
Kritharides, L. [1 ,5 ]
Robertson, G. [2 ]
机构
[1] Univ Sydney, ANZAC Res Inst, Vasc Biol Grp, Sydney, NSW, Australia
[2] Univ Sydney, ANZAC Res Inst, Canc Pharmacol Unit, Sydney, NSW, Australia
[3] Concord Repatriat Gen Hosp, Dept Haematol, Concord, Australia
[4] Westmead Hosp, Dept Haematol, Westmead, NSW, Australia
[5] Concord Repatriat Gen Hosp, Dept Cardiol, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
blood coagulation; cachexia; interleukin-6; mice; thrombin; TISSUE FACTOR; VENOUS THROMBOEMBOLISM; COAGULATION; PLASMA; HYPOFIBRINOLYSIS; ADENOCARCINOMA; METASTASIS; MECHANISMS; PREDICTION; PLATELETS;
D O I
10.1111/jth.13612
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cancer cachexia and cancer-associated thrombosis are potentially fatal outcomes of advanced cancer, which have not previously been mechanistically linked. The colon 26 (C26) carcinoma is a well-established mouse model of complications of advanced cancer cachexia, partially dependent on high levels of interleukin-6 (IL-6) produced by the tumor. Objectives To assess if cancer cachexia altered the coagulation state and if this was attributable to tumor IL-6 production. Methods In male BALB/c*DBA2 (F1 hybrid) mice with a C26 tumor we used modified calibrated automated thrombogram and fibrin generation (based on overall hemostatic potential) assays to assess the functional coagulation state, and also examined fibrinogen, erythrocyte sedimentation rate (ESR), platelet count, tissue factor pathway inhibitor (TFPI) and hepatic expression of coagulation factors by microarray. C26 mice were compared with non-cachectic NC26, pair-fed and sham control mice. IL-6 expression in C26 cells was knocked down by lentiviral shRNA constructs. Results C26 mice with significant weight loss and highly elevated IL-6 had elevated thrombin generation, fibrinogen, ESR, platelets and TFPI compared with all control groups. Fibrin generation was elevated compared with pair-fed and sham controls but not compared with NC26 tumor mice. Hepatic expression of coagulation factors and fibrinolytic inhibitors was increased. Silencing IL-6 in the tumor significantly, but incompletely, attenuated the increased thrombin generation, fibrinogen and TFPI. Conclusions Cachectic C26 tumor-bearing mice are in a hypercoagulable state, which is partly attributable to IL-6 release by the tumor. The findings support the importance of the coagulation state in cancer cachexia and the clinical utility of anti-inflammatory interventions.
引用
收藏
页码:477 / 486
页数:10
相关论文
共 51 条
  • [1] Possible Role for Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia
    Ando, Katsutoshi
    Takahashi, Fumiyuki
    Motojima, Shinji
    Nakashima, Kei
    Kaneko, Norihiro
    Hoshi, Kazuei
    Takahashi, Kazuhisa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) : E69 - E72
  • [2] Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma
    Antovic, A
    Blombäck, M
    Sten-Linder, M
    Petrini, P
    Holmström, M
    He, S
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2005, 16 (08) : 585 - 596
  • [3] Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse
    Aulino, Paola
    Berardi, Emanuele
    Cardillo, Veronica M.
    Rizzuto, Emanuele
    Perniconi, Barbara
    Ramina, Carla
    Padula, Fabrizio
    Spugnini, Enrico P.
    Baldi, Alfonso
    Faiola, Fabio
    Adamo, Sergio
    Coletti, Dario
    [J]. BMC CANCER, 2010, 10
  • [4] Prediction of Venous Thromboembolism in Patients With Cancer by Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study
    Ay, Cihan
    Dunkler, Daniela
    Simanek, Ralph
    Thaler, Johannes
    Koder, Silvia
    Marosi, Christine
    Zielinski, Christoph
    Pabinger, Ingrid
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 2099 - 2103
  • [5] Elevated clotting factor levels and venous thrombosis
    Bertina, RM
    [J]. PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2003, 33 (5-6) : 395 - 400
  • [6] Malignancies, prothrombotic mutations, and the risk of venous thrombosis
    Blom, JW
    Doggen, CJM
    Osanto, S
    Rosendaal, FR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06): : 715 - 722
  • [7] STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia
    Bonetto, Andrea
    Aydogdu, Tufan
    Kunzevitzky, Noelia
    Guttridge, Denis C.
    Khuri, Sawsan
    Koniaris, Leonidas G.
    Zimmers, Teresa A.
    [J]. PLOS ONE, 2011, 6 (07):
  • [8] Regulation of thrombin generation by TFPI in plasma without and with heparin
    Brodin, Ellen
    Appelbom, Hege
    Osterud, Warne
    Hilden, Ida
    Petersen, Lars C.
    Hansen, John-Jarne
    [J]. TRANSLATIONAL RESEARCH, 2009, 153 (03) : 124 - 131
  • [9] PLASMINOGEN-ACTIVATOR IN NORMAL AND TUMOR-BEARING MICE
    BRUESCH, MR
    JOHNSON, GL
    PALACKDHARRY, CS
    WEBER, MJ
    CARL, PL
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1983, 32 (01) : 121 - 126
  • [10] Global assays of hemostasis
    Brummel-Ziedins, Kathleen E.
    Wolberg, Alisa S.
    [J]. CURRENT OPINION IN HEMATOLOGY, 2014, 21 (05) : 395 - 403